MX2014008702A - Composiciones derivadas de la quitosana. - Google Patents
Composiciones derivadas de la quitosana.Info
- Publication number
- MX2014008702A MX2014008702A MX2014008702A MX2014008702A MX2014008702A MX 2014008702 A MX2014008702 A MX 2014008702A MX 2014008702 A MX2014008702 A MX 2014008702A MX 2014008702 A MX2014008702 A MX 2014008702A MX 2014008702 A MX2014008702 A MX 2014008702A
- Authority
- MX
- Mexico
- Prior art keywords
- chitosan
- neoplasms
- derived compositions
- malignant
- derived
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Otolaryngology (AREA)
- Optics & Photonics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Electromagnetism (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención está relacionada en general con los compuestos terapéuticos que comprenden compuestos derivados de quitosana empleados junto con métodos para tratar neoplasmas, como por ejemplo, neoplasmas malignos del pulmón, tiroides y riñón, y otros tipos de neoplasmas malignos, y otros trastornos médicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261588783P | 2012-01-20 | 2012-01-20 | |
PCT/US2013/021903 WO2013109732A2 (en) | 2012-01-20 | 2013-01-17 | Chitosan-derived compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014008702A true MX2014008702A (es) | 2015-04-08 |
MX371275B MX371275B (es) | 2020-01-23 |
Family
ID=48799808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008702A MX371275B (es) | 2012-01-20 | 2013-01-17 | Composiciones derivadas de la quitosana. |
Country Status (30)
Country | Link |
---|---|
US (1) | US20150018748A1 (es) |
EP (2) | EP3831393A1 (es) |
JP (1) | JP6180436B2 (es) |
KR (5) | KR20200139254A (es) |
CN (2) | CN110038125A (es) |
AU (1) | AU2013209716B2 (es) |
BR (1) | BR112014017426B1 (es) |
CA (1) | CA2861367C (es) |
CL (1) | CL2014001880A1 (es) |
CO (1) | CO7101239A2 (es) |
CY (1) | CY1123490T1 (es) |
DK (1) | DK2804611T3 (es) |
EA (1) | EA030148B1 (es) |
EC (1) | ECSP14014778A (es) |
ES (1) | ES2829899T3 (es) |
HK (1) | HK1210019A1 (es) |
HR (1) | HRP20201647T1 (es) |
HU (1) | HUE051744T2 (es) |
IL (1) | IL233649B (es) |
LT (1) | LT2804611T (es) |
MX (1) | MX371275B (es) |
MY (1) | MY191932A (es) |
NZ (1) | NZ628433A (es) |
PE (1) | PE20142325A1 (es) |
PL (1) | PL2804611T3 (es) |
PT (1) | PT2804611T (es) |
RS (1) | RS61257B1 (es) |
SG (1) | SG11201403943TA (es) |
SI (1) | SI2804611T1 (es) |
WO (1) | WO2013109732A2 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11773188B2 (en) | 2012-01-20 | 2023-10-03 | Immunophotonics, Inc | Chitosan-derived compositions |
US11111316B2 (en) * | 2012-01-20 | 2021-09-07 | Immunophotonics, Inc. | Chitosan-derived compositions |
CN107200788B (zh) * | 2017-05-11 | 2020-04-14 | 暨南大学 | 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用 |
US20200010575A1 (en) * | 2018-07-05 | 2020-01-09 | Immunophotonics, Inc. | Semi-synthetic biopolymers for use in treating proliferative disorders |
WO2020060131A1 (ko) * | 2018-09-19 | 2020-03-26 | 주식회사 엘지화학 | LiOH를 포함하는 리튬 이차 전지용 전극, 그의 제조방법, 및 상기 전극을 포함하는 리튬 이차 전지 |
EP3817773A4 (en) | 2018-11-26 | 2021-09-15 | Forty Seven, Inc. | HUMANIZED ANTIBODIES AGAINST C-KIT |
WO2023028311A1 (en) * | 2021-08-27 | 2023-03-02 | Immunophotonics, Inc. | Glycated chitosans for treatment of viral infections |
WO2024133580A1 (en) | 2022-12-20 | 2024-06-27 | Lytix Biopharma As | Medical products containing an aqueous formulation of a peptide |
WO2024133588A1 (en) | 2022-12-20 | 2024-06-27 | Lytix Biopharma As | Compositions comprising an oncolytic peptide and chitosan |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US591200A (en) | 1897-10-05 | Safe-lock | ||
US4424346A (en) * | 1981-06-04 | 1984-01-03 | Canadian Patents And Development Ltd. | Derivatives of chitins, chitosans and other polysaccharides |
US5095030A (en) | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5002962A (en) | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
US5214036A (en) | 1990-03-08 | 1993-05-25 | University Of British Columbia | Benzoporphyrin derivatives for photodynamic therapy |
US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
US5283225A (en) | 1992-11-24 | 1994-02-01 | Eastman Kodak Company | Underlayer of dye-donor element for thermal dye transfer systems |
US5912000A (en) * | 1994-09-23 | 1999-06-15 | Zonagen, Inc. | Chitosan induced immunopotentiation |
US6316007B1 (en) * | 1995-04-04 | 2001-11-13 | Wound Healing Of Oklahoma | Combined physical and immunotherapy for cancer |
WO1996031237A2 (en) * | 1995-04-04 | 1996-10-10 | Wound Healing Of Oklahoma | Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant |
TW389694B (en) * | 1995-08-17 | 2000-05-11 | Novartis Ag | Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics |
JP4606586B2 (ja) * | 1998-11-10 | 2011-01-05 | 株式会社ネーテック | 機能性キトサン誘導体 |
US20020022032A1 (en) * | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
US20040047892A1 (en) * | 2000-11-15 | 2004-03-11 | Desrosiers Eric Andre | Filler composition for soft tissue augmentation and reconstructive surgery |
US6756363B1 (en) * | 2000-11-17 | 2004-06-29 | Wound Healing Of Oklahoma, Inc. | Solutions and films of glycated chitosan |
US20110130473A1 (en) * | 2007-11-13 | 2011-06-02 | Bio-Technology General (Israel) Ltd. | Dilute filtration sterilization process for viscoelastic biopolymers |
CN101440136B (zh) * | 2008-12-12 | 2011-07-06 | 中国海洋大学 | 胺糖化几丁聚糖复合物的制备方法 |
-
2013
- 2013-01-17 CN CN201910104579.9A patent/CN110038125A/zh active Pending
- 2013-01-17 WO PCT/US2013/021903 patent/WO2013109732A2/en active Application Filing
- 2013-01-17 PE PE2014001126A patent/PE20142325A1/es not_active Application Discontinuation
- 2013-01-17 EA EA201491402A patent/EA030148B1/ru not_active IP Right Cessation
- 2013-01-17 PT PT137385050T patent/PT2804611T/pt unknown
- 2013-01-17 CN CN201380006011.4A patent/CN104619310A/zh active Pending
- 2013-01-17 RS RS20201245A patent/RS61257B1/sr unknown
- 2013-01-17 NZ NZ628433A patent/NZ628433A/en unknown
- 2013-01-17 KR KR1020207034027A patent/KR20200139254A/ko not_active IP Right Cessation
- 2013-01-17 SG SG11201403943TA patent/SG11201403943TA/en unknown
- 2013-01-17 KR KR1020177007047A patent/KR20170032490A/ko active Search and Examination
- 2013-01-17 ES ES13738505T patent/ES2829899T3/es active Active
- 2013-01-17 KR KR1020147021861A patent/KR20140117487A/ko active Search and Examination
- 2013-01-17 JP JP2014553403A patent/JP6180436B2/ja active Active
- 2013-01-17 MX MX2014008702A patent/MX371275B/es active IP Right Grant
- 2013-01-17 US US14/372,586 patent/US20150018748A1/en not_active Abandoned
- 2013-01-17 KR KR1020187032309A patent/KR20180123727A/ko not_active Application Discontinuation
- 2013-01-17 BR BR112014017426-1A patent/BR112014017426B1/pt active IP Right Grant
- 2013-01-17 EP EP20198582.7A patent/EP3831393A1/en active Pending
- 2013-01-17 EP EP13738505.0A patent/EP2804611B1/en active Active
- 2013-01-17 AU AU2013209716A patent/AU2013209716B2/en active Active
- 2013-01-17 CA CA2861367A patent/CA2861367C/en active Active
- 2013-01-17 PL PL13738505T patent/PL2804611T3/pl unknown
- 2013-01-17 KR KR1020227005616A patent/KR20220028153A/ko not_active Application Discontinuation
- 2013-01-17 HU HUE13738505A patent/HUE051744T2/hu unknown
- 2013-01-17 DK DK13738505.0T patent/DK2804611T3/da active
- 2013-01-17 MY MYPI2014701927A patent/MY191932A/en unknown
- 2013-01-17 SI SI201331814T patent/SI2804611T1/sl unknown
- 2013-01-17 LT LTEP13738505.0T patent/LT2804611T/lt unknown
-
2014
- 2014-07-15 IL IL233649A patent/IL233649B/en active IP Right Grant
- 2014-07-15 CL CL2014001880A patent/CL2014001880A1/es unknown
- 2014-07-18 CO CO14156300A patent/CO7101239A2/es unknown
- 2014-08-19 EC ECIEPI201414778A patent/ECSP14014778A/es unknown
-
2015
- 2015-10-30 HK HK15110753.9A patent/HK1210019A1/xx unknown
-
2020
- 2020-10-13 HR HRP20201647TT patent/HRP20201647T1/hr unknown
- 2020-11-06 CY CY20201101048T patent/CY1123490T1/el unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
US9414967B2 (en) | 2014-04-16 | 2016-08-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY191932A (en) | Chitosan-derived compositions | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
PH12015500825A1 (en) | Substituted benzene compounds | |
EA201590987A1 (ru) | Соединения и способы их применения | |
MX2020009223A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
JO3438B1 (ar) | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس | |
GB201106750D0 (en) | Novel compounds | |
MX2015006478A (es) | Inhibidores de glutaminasa y metodos de empleo. | |
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
IN2014DN09228A (es) | ||
MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
MY184721A (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis | |
NZ629475A (en) | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines | |
IN2013MU03429A (es) | ||
NZ745950A (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
TN2014000207A1 (en) | Anti il-36r antibodies | |
TN2013000202A1 (en) | Spiro-oxindole mdm2 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |